One-Year Outcomes After Belatacept Conversion in Adolescent Kidney Transplant Recipients
Although rejection rates in pediatric patients on belatacept seemed higher than in adult cohorts, they were not significantly different from adolescent patients on CNI, underscoring the challenges related to nonadherence in this population. Tailored immunosuppression strategies, including belatacept, may offer benefits for selected adolescents, but further studies are necessary to define optimal patient selection.
Authors
- Élodie Cheyssac
- Barry L. Warshaw
- Charlotte Duneton (ORCID: https://orcid.org/0000-0002-0603-1970)
- Rochelle Liverman (ORCID: https://orcid.org/0000-0001-6653-891X)
- Julien Hogan (ORCID: https://orcid.org/0000-0003-4838-9417)
- Anne‐Laure Sellier‐Leclerc (ORCID: https://orcid.org/0000-0001-9902-0850)
- Roshan George (ORCID: https://orcid.org/0000-0003-3853-967X)
- Rouba Garro (ORCID: https://orcid.org/0000-0003-2936-3676)
- Véronique Baudouin (ORCID: https://orcid.org/0000-0003-0242-1936)
- Beatrice Beauval
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Centre Hospitalier Universitaire de La Réunion (RE)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospices Civils de Lyon (FR)
- Mother Hospital (IN)
- Hôpital Robert-Debré (FR)
- Laboratoire de Recherche Vasculaire Translationnelle (FR)
- Children's Healthcare of Atlanta (US)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1016/j.ekir.2025.03.016
- Citations
- 3
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.96